Shares of Shilpa Medicare gain 6.20 per cent! Heres why?

The company has acquired expertise with compliance-oriented research for the development of novel and safer drug delivery such as oral strips keeping in mind patient convenience.

One of the world’s leading suppliers of oncology and non-oncology API's and intermediates, Shilpa Medicare has announced that it has launched PRUCALSHIL (Prucalopride) orally disintegrating strips (‘1 mg and 2 mg’) in India, a unique formulation developed for the first time in the world. The company has developed a novel ‘Orally Disintegrating Strip (ODS)’ formulation for Prucalopride and obtained subsequent approval from the Drug Control General of India.

The product will help build the company’s gastro portfolio and going forward they also have plans to add more products to the gastro basket. Prucalopride is used for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief. Prucalopride medicine in the form of orally disintegrating strips is the most convenient dosage form for geriatric patients.

Orally Disintegrating Strips technology is emerging in novel drug delivery formulations. The company has acquired expertise with compliance-oriented research for the development of novel and safer drug delivery such as oral strips keeping in mind patient convenience. Orally disintegrating strips have an advantage such as greater dissolution due to large surface area, more patient compliance than oral tablets, no risk of choking and better taste masking, etc.

Shares of Shilpa Medicare recorded an intra-day high of Rs 562.15 per share on NSE.